LAUSR

835 cation as a CD8+ T-cell “lymphoproliferative disorder” is debated [7]. In contrast to PCAETCL, which requires aggressive polychemotherapy due to an ominous prognosis [2, 8], FUMHD is treated with systemic steroids, methotrexate [9], and/or intravenous immunoglobulins (IVIg) [10]. Our patient was treated with three methylprednisolone pulses (500 mg/d), then oral prednisone (1 mg/kg), methotrexate (15 mg/week), and IVIg (2 g/kg monthly). The evolution was favourable, with rapid improvement of the general condition, healing of skin lesions, and disappearance of lung nodules on the control CT scan performed three months after diagnosis. No relapse has occurred after a nine-month follow-up period.